SCHEMBL30749020

SCHEMBL30749020

CC1(C)CN(c2ccc(Oc3ccccc3)cc2)c2nc(Cl)ncc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 3/20 0.40
MAPT P10636 1/20 0.36
HRH4 Q9H3N8 3/20 0.35
PLCG1 P19174 1/20 0.34
CTSG P08311 1/20 0.34
CMA1 P23946 1/20 0.34
TNK2 Q07912 1/20 0.33
LTA4H P09960 1/20 0.33
KAT2B Q92831 1/20 0.32
STK17B O94768 1/20 0.32
STK17A Q9UEE5 1/20 0.32
MGLL Q99685 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 1/20 0.32
CASP3 P42574 1/20 0.32
RAB9A P51151 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749030 0.86 PIN1 (0.40) PIN1MAPTPLCG1CTSGCMA1
SCHEMBL30748853 0.84 POLB (0.36) HRH4PLCG1TNK2LTA4HSMN1; SMN2
SCHEMBL30748969 0.83 PLCG1 (0.35) HRH4PLCG1TNK2KAT2BMGLL
SCHEMBL30749008 0.83 PLCG1 (0.33) HRH4PLCG1TNK2LTA4HKAT2B
SCHEMBL30748843 0.77 PDE4B (0.43) PIN1MAPTCTSGCMA1MGLL
SCHEMBL30748965 0.76 PSEN1 (0.41)
SCHEMBL31691357 0.74 MCHR2 (0.33) HRH4LTA4H
SCHEMBL30748809 0.72 CCNE1 (0.45) PIN1MAPTPLCG1MGLL
SCHEMBL30749107 0.71 PSEN1 (0.45) PIN1MAPTPLCG1TNK2LTA4H
SCHEMBL16691351 0.70 MAPT (0.42) PIN1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT PIN1 944/4885MAPT 3029/4885HRH4 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.